Renegar R H, Bazer F W, Roberts R M
Biol Reprod. 1982 Dec;27(5):1247-60. doi: 10.1095/biolreprod27.5.1247.
Placental transport of uteroferrin (Uf), the progesterone-induced iron transport glycoprotein, and its distribution within the fetus were investigated by the peroxidase-antiperoxidase bridge (PAP) technique. In Experiment 1, Uf was localized in endometrial and placental tissues taken from gilts on Days 60, 75, 90 and 105 of pregnancy. Uteroferrin was observed within cells of the endometrial glands and surface epithelium adjacent to placental areolae but not in endometrial surface epithelium between areolae. Heavy staining for Uf was observed in cells of the areolae and was associated with both supra- and infranuclear cytoplasmic vesicles. Vesicles located within the infranuclear cytoplasm were occasionally observed to be releasing their contents into capillaries surrounding the areolae. In Experiment 2, Uf was measured by radioimmunoassay in blood samples taken from the umbilical vein and artery of fetuses on Day 75 of pregnancy. Uteroferrin concentrations were greater (P less than 0.07) in umbilical vein blood (79.8 +/- 13.1 ng/ml) than in umbilical artery blood (43.9 +/- 13.1 ng/ml). Uteroferrin binding by Day 75 fetal liver membranes was examined in Experiment 3. Binding of 125I-Uf increased linearly with increasing quantities of membrane protein and binding of 125I-Uf was competitively inhibited by adding unlabeled Uf to the assay. In Experiment 4, urine samples were taken from Day 75 fetuses and assayed for beta-mercaptoethanol activated acid phosphatase activity which is indicative of Uf. In addition, urine proteins were analyzed for Uf by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and Ouchterlony double immunodiffusion (ID). Acid phosphatase specific activity was 3.37 +/- 1.83 mumol substrate hydrolyzed/10 min per mg protein. Uteroferrin was detected in two of three urine samples by 2D-PAGE and in three of eight samples by ID. In Experiment 5, tissue distribution of Uf was determined by the PAP technique in liver and kidney tissue taken from fetuses on Day 75 of pregnancy. Staining for Uf was observed in collecting ducts and proximal tubules of kidney tissue, but staining was not observed in liver tissue. These results indicate that Uf is transported by the areolae into the chorioallantoic capillaries and to the fetus by the umbilical vein. Within the fetus Uf is either bound by the liver, probably to supply iron for hematopoiesis, or cleared by the kidney and transported within the urine to the allantoic sac to serve as a temporary iron storage reservoir.
采用过氧化物酶-抗过氧化物酶桥联(PAP)技术,研究了子宫铁蛋白(Uf,一种由孕酮诱导的铁转运糖蛋白)的胎盘转运及其在胎儿体内的分布。在实验1中,于妊娠第60、75、90和105天从后备母猪获取子宫内膜和胎盘组织,对Uf进行定位。在与胎盘乳晕相邻的子宫内膜腺细胞和表面上皮细胞中观察到子宫铁蛋白,但在乳晕之间的子宫内膜表面上皮细胞中未观察到。在乳晕细胞中观察到Uf的强染色,且与核上和核下细胞质囊泡有关。偶尔观察到位于核下细胞质中的囊泡将其内容物释放到乳晕周围的毛细血管中。在实验2中,通过放射免疫分析法测定妊娠第75天胎儿脐静脉和动脉血样中的Uf。脐静脉血中子宫铁蛋白浓度(79.8±13.1 ng/ml)高于脐动脉血(43.9±13.1 ng/ml)(P<0.07)。在实验3中,检测了妊娠第75天胎儿肝细胞膜对子宫铁蛋白的结合。125I-Uf的结合量随膜蛋白量的增加呈线性增加,且在测定中加入未标记的Uf可竞争性抑制125I-Uf的结合。在实验4中,采集妊娠第75天胎儿的尿样,检测β-巯基乙醇激活的酸性磷酸酶活性,该活性可指示Uf。此外,通过二维聚丙烯酰胺凝胶电泳(2D-PAGE)和双向免疫扩散法(ID)分析尿蛋白中的Uf。酸性磷酸酶比活性为3.37±1.83 μmol底物水解/10 min·mg蛋白。通过2D-PAGE在三份尿样中的两份中检测到子宫铁蛋白,通过ID在八份尿样中的三份中检测到。在实验5中,采用PAP技术确定妊娠第75天胎儿肝脏和肾脏组织中Uf的组织分布。在肾脏组织的集合管和近端小管中观察到Uf染色,但在肝脏组织中未观察到染色。这些结果表明,Uf通过乳晕转运至绒毛膜尿囊毛细血管,并通过脐静脉输送至胎儿。在胎儿体内,Uf要么被肝脏结合,可能用于为造血提供铁,要么被肾脏清除,并在尿液中转运至尿囊,作为临时的铁储存库。